Page 2 - லுட்விக் மாக்ஸிமிலியன் பல்கலைக்கழகம் முனிச் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

®         Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces the European Commission (EC) has approved the marketing authorisation for Efmody ® (hydrocortisone modified-release hard capsules - development name Chronocort ®) as treatment of adult and adolescent patients (12 years and older) with the rare condition congenital adrenal hyperplasia (CAH). This decision by the EC follows the positive opinion issued by the European Medicines Agency (EMA) in March 2021.   To facilitate timely commercial availability, Diurnal has already commenced market access activities in its target European territories, with the first commercial launch anticipated in Q3 2021. The Company intends to mirror its strategy for Alkindi

United kingdomNicole reischFoster mitchellEmma earlFreddy crossleyMartin whitakerRichard bungayAlex davisSimon conwayRupert deardenEuropean commission for efmodyEuropean unionEuropean medicines agencyPanmure gordon united kingdom limited nominated adviserEuropean commissionDiurnal group